Clik here to view.
#ESMO24: After landing a key win in a common cancer condition, Pfizer faces a...
BARCELONA — One of this weekend’s sleeper data presentations at Europe’s biggest oncology conference puts Pfizer in a leading position in a common cancer condition with no approved treatments in the US...
View ArticleClik here to view.
#ESMO24: Sun, surprises and new summits at Europe’s biggest cancer conference
BARCELONA — More than 33,000 oncologists, medical researchers, biopharma leaders and other delegates attended Europe’s largest cancer meeting over the past few days in Spain, with more than 181...
View ArticleClik here to view.
Bad trip: How culture conflict and a need for cash nearly broke Lykos
In early 2023, the founder of the psychedelic medicine company Lykos Therapeutics met with a potential investor for dinner, feeling out the chemistry for a financial — and personal — relationship that...
View ArticleCigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report
Cigna, the owner of one of the top pharmacy benefit managers, is suing the Federal Trade Commission and Commissioner Lina Khan, and asking them to pull a July report that slammed the drug industry...
View ArticleCapricor expands DMD pact with Nippon Shinyaku; AbbVie’s new eye deal
Plus, news about Vigil Neuroscience, AC Immune and Athira Pharma: Capricor Therapeutics, Nippon Shinyaku expand commercial pact into Europe: The new deal builds off an existing partnership for a...
View ArticleCoherus warns of limited cancer drug supply due to third-party ‘capacity...
Supplies of Coherus Biosciences’ biosimilar version of the white blood cell-stimulating drug Neulasta will be “substantially depleted” through mid-October because of production constraints at a...
View ArticleClik here to view.
CDMO Serán sets out to build first commercial facility, with a $200M...
Small molecule contract manufacturer Serán Bioscience is building its first commercial-scale manufacturing facility, backed by a $200 million investment from Bain Capital and others. “We are pushing...
View ArticleConducting trials via routine clinical practice: FDA explains how in new...
The FDA on Tuesday firmed up its position that in some limited circumstances, clinical trial data may be obtained from routine clinical practice. The use of such trials could potentially reduce the...
View ArticleNovartis’ Kisqali snags FDA approval to reduce recurrence in patients with...
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast cancer market. The FDA approved the oral treatment Tuesday for patients with...
View ArticleClik here to view.
All of 23andMe's independent board members resign over disagreements with CEO
All seven independent directors of 23andMe’s board have immediately resigned, they wrote in a public letter Tuesday, expressing concerns over their differing views with CEO Anne Wojcicki. The chief...
View ArticleClik here to view.
Theratechnologies' HIV drug to face supply issues in 2025 over third-party...
Another pharma company is facing supply constraints because of third-party contract manufacturing issues. On Tuesday, Theratechnologies warned there is a risk its lipodystrophy drug for HIV, Egrifta...
View ArticleClik here to view.
Former Amazon Pharmacy execs back Mevo, a startup bringing online prescribing...
A startup in Brazil that lets people easily buy medicine online by combining a consumer-friendly experience with prescription tech for providers just raised a $19 million Series B round. Mevo has...
View ArticleClik here to view.
After I was diagnosed with Merkel cell carcinoma, I discovered how a band of...
Bioregnum Opinion Column by John Carroll It all started to look seriously bad when my legs began to swell up, which I initially — stupidly — shrugged off. By the time it became apparent that my kidneys...
View ArticleClik here to view.
Novo Nordisk signs genetic medicine pact, inking deal with NanoVation
Novo Nordisk is doubling down on its investment in genetic medicine-based biotechs, inking a new collaboration with a lipid nanoparticle developer worth up to $600 million. The new deal announced...
View ArticleWith few efficacy details, Insilico claims a Phase 2a win in latest AI readout
Insilico Medicine reported Phase 2a results for its lead program, saying the study achieved its primary endpoint of safety and tolerability. But the efficacy data it released were much more vague. In a...
View ArticleClik here to view.
Roivant makes another deal, selling Dermavant to Organon for up to $1.2B
Roivant is once again reaping the benefits of its bespoke business model. This time, it’s selling Dermavant to Organon for up to $1.2 billion. Most of that money — $950 million — is available via...
View ArticleSenators tell FDA that ‘greater action is needed’ to use manufacturing tech...
Sens. Marco Rubio (R-FL) and Angus King (I-ME) have told the FDA that “considerable work” needs to be done to address how advanced manufacturing technologies can be used to improve US domestic supply...
View ArticleKeytruda adds new FDA approval for a rare form of mesothelioma
Keytruda is already approved in more than 40 different oncology indications, but its latest label expansion is a first for the cancer blockbuster. Merck announced Wednesday that the FDA cleared the...
View ArticleFDA cancels Applied Therapeutics adcomm, shares skyrocket 65%
New York-based Applied Therapeutics disclosed on Wednesday that the FDA has canceled an October advisory committee meeting for its potential treatment for the genetic disorder classic galactosemia,...
View ArticleClik here to view.
What does today's Fed rate cut mean for biotech, pharma and venture capital?
The Federal Reserve made its long-anticipated interest rate cuts on Wednesday, lowering rates by a half of a percentage point. It’s the first time the Fed has cut interest rates since March 2020, at...
View Article